Summary
In 10 healthy volunteers the time course of cardiac beta-adrenoceptor blocking activity, plasma levels and cumulative urinary excretion of pindolol were compared during a 4-day course of pindolol 5 mg (Visken®) t. d. s., and one tablet of pindolol 20 mg retard (Visken® retard) once a day. After oral administration of the 20 mg retard tablet, plasma concentrations of pindolol higher than half the maximum value (1/2 Cp (tmax)) were maintained about 2.5 times as long as after administration of the conventional 5 mg tablet. This is evidence for an important and marked retardation of drug release. During treatment with pindolol 20 mg retard once daily, cardiac beta-adrenoceptor blockade, measured by the reduction in exercise-induced tachycardia and in the exercise-induced rise in systolic blood pressure, at almost all times throughout the 24 h period was at least as great as during treatment with pindolol 5 mg t. d. s. This suggests that patients successfully treated with pindolol 5 mg t. d. s. can be maintained with the same beta-adrenoceptor blockade by a single tablet of pindolol 20 mg retard once daily.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aellig WH (1976) Beta-adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol 3: 251–257
Aellig WH (1978) Comparison of the duration of action of pindolol and slow release exprenolol in healthy volunteers. Eur J Clin Pharmacol 14: 167–169
Rosenthal J, Kaiser H, Hammerschmidt D, Welzel D (1977) Praxis der Hochdrucktherapie mit einem Beta-Rezeptorenblocker — eine Multizenterstudie mit Visken 15 mg. Med Welt 28: 1969–1974
Frithz G (1978) Initiation of once daily pindolol treatment. Br med J 1: 302
Robinson BF (1967) Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. Circulation 35: 1073–1083
Aellig WH, Nüesch E, Pacha W (1981) A pharmacokinetic comparison of pindolol 30 mg retard and a conventional tablet. Eur J Clin Pharmacol (in press)
Pacha WL (1969) A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB 46), a beta-blocking agent, in plasma and urine. Experientia 25: 802
Meier J, Nüesch E, Schmidt R (1974) Pharmacokinetic criteria for the evaluation of retard formulations. Eur J Clin Pharmacol 7: 429–432
Berman M, Weiss M (1975) User's manual for SAAM 26. National Technical Information Service. US Department of Commerce, Springfield, VA
Meier J (1979) Beta-adrenoceptor-blocking agents: Pharmacokinetic differences and their clinical implications illustrated on pindolol. Cardiology 64 (Suppl 1): 1–13
Meier J, Nüesch E (1977) Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect. Br J Clin Pharmacol 4: 371–372
Gugler R, Bodem G (1978) Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol 13: 13–16
Aellig WH (1976) Klinisch-pharmakologische Untersuchungen mit Pindolol nach intravenöser und oraler Verabreichung. Adv Clin Pharmacol 11: 9–13
Lang E, Fitscha P, Schiess W (1979) Der Betablocker Pindolol in der Therapie der Angina pectoris — Bericht über eine multizentrische kontrollierte Studie. Wien Med Wochenschr 129: 484–488
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aellig, W.H., Narjes, H.H., Nüesch, E. et al. A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet. Eur J Clin Pharmacol 20, 179–183 (1981). https://doi.org/10.1007/BF00544595
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544595